Want to see CTMX full AI Analyst Report?
CTMX Stock Chart & Stats
$4.82
-$0.06(-5.83%)
At close: 4:00 PM EST
$4.82
-$0.06(-5.83%)
Day’s Range― - ―
52-Week Range$1.72 - $8.21
Previous CloseN/A
Volume1.08M
Average Volume (3M)5.06M
Market Cap
$788.08M
Enterprise Value$489.33
Total Cash (Recent Filing)$346.71M
Total Debt (Recent Filing)$2.86M
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Aug 06, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding217,702,910
10 Day Avg. Volume3,623,906
30 Day Avg. Volume5,058,364
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.93
Price to Sales (P/S)7.71
P/FCF Ratio-7.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.83Price Target Upside145.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$30.75M
Bulls Say, Bears Say
Bulls Say
Expanded Regeneron CollaborationThe expanded Regeneron partnership materially increases long-term optionality and non-dilutive funding. With $37M already triggered and up to ~$4B in potential milestones, the deal diversifies program risk, funds R&D cadence, and strengthens commercialization economics if partnered assets advance.
Material Cash Runway Into H2 2028A cash balance near $347M provides durable financing headroom to execute planned registrational activities for Varseta-M and multiple 2026–2027 readouts. This reduces near-term financing pressure and enables prioritized R&D investment without immediate dilution or forced asset sales.
Probody Platform Progress & Varseta‑M Clinical MomentumDemonstrated ORR and PFS materially above current late-line standards validate the Probody approach and support a credible path to a registrational study. Completed dose optimization and planned combinations expand development pathways, strengthening long-term product and platform value if confirmed in pivotal trials.
Bears Say
Sharp Revenue Decline And Persistent Cash BurnRevenue volatility tied to lumpy collaboration milestones and ~-$80M annual cash burn create sustained financing needs. Even with a strong current cash balance, the company remains dependent on milestone receipts, partnerships or equity raises, which can constrain strategic flexibility and increase dilution risk over time.
Principal Safety Risk: Grade 3 DiarrheaTreatment-limiting Grade 3 diarrhea is a structural clinical risk that could force dose reductions, narrower indications, or additional mitigation burdens. Until larger optimization cohorts and longer follow-up show consistent manageability, safety may limit regulatory approval scope and commercial adoption, especially in combinations.
Expanded Share Authorization Increases Dilution RiskWhile expanded authorization aids talent retention and financing flexibility, it structurally raises the potential for future equity issuance. For a clinical-stage biotech with ongoing cash burn and lumpy milestone revenue, this increases the likelihood of dilution when additional capital is needed to fund registrational programs.
CytomX Therapeutics News
CTMX FAQ
What was CytomX Therapeutics Inc.’s price range in the past 12 months?
CytomX Therapeutics Inc. lowest stock price was $1.72 and its highest was $8.21 in the past 12 months.
What is CytomX Therapeutics Inc.’s market cap?
CytomX Therapeutics Inc.’s market cap is $788.08M.
When is CytomX Therapeutics Inc.’s upcoming earnings report date?
CytomX Therapeutics Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were CytomX Therapeutics Inc.’s earnings last quarter?
CytomX Therapeutics Inc. released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.121 by $0.021.
Is CytomX Therapeutics Inc. overvalued?
According to Wall Street analysts CytomX Therapeutics Inc.’s price is currently Undervalued.
Does CytomX Therapeutics Inc. pay dividends?
CytomX Therapeutics Inc. does not currently pay dividends.
What is CytomX Therapeutics Inc.’s EPS estimate?
CytomX Therapeutics Inc.’s EPS estimate is -0.08.
How many shares outstanding does CytomX Therapeutics Inc. have?
CytomX Therapeutics Inc. has 217,702,910 shares outstanding.
What happened to CytomX Therapeutics Inc.’s price movement after its last earnings report?
CytomX Therapeutics Inc. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.121. Following the earnings report the stock price went down -0.5%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc.?
Currently, no hedge funds are holding shares in CTMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytomX Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.83 (145.50% Upside)
$11.83 (145.50% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
264.84%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
CTMX Stock 12 Month Forecast
Average Price Target
$11.83
▲(145.50% Upside)
Technical Analysis
Ownership Overview
0.91% Insiders
15.49% Mutual Funds
0.30% Other Institutional Investors
69.41% Public Companies and
Individual Investors